Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 61-71

  Wei, Xierong ^a   Liu, Xin ^a   Dobbs, Trudy ^a   Kuehl, Debra ^a   Nkengasong, John N ^a   Hu, Dale J ^a   Parekh, Bharat S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; ONE WELL LIMITING ANTIGEN AVIDITY ENZYME IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROCONVERSION; TWO WELL AVIDITY INDEX ENZYME IMMUNOASSAY;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGENS, VIRAL; ESCHERICHIA COLI; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; THAILAND;

EID: 76449097534     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0133     Document Type: Article

References (46)

1. Clements MS, Prestage G, Grulich A, Van de Ven P, Kippax S, and Law MG: Modeling trends in HIV incidence among homosexual men in Australia 1995-2006. J Acquir Immune Defic Syndr 2004;35:401-406.
2. Holtgrave DR: Estimation of annual HIV transmission rates in the United States, 1978-2000. J Acquir Immune Defic Syndr 2004;35:89-92.
3. Sill AM, Kreisel K, Deeds BG, et al.: Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infections. J Clin Lab Anal 2007;21:40-45.
4. Constantine NT, Sill AM, Jack N, et al.: Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy. J Acquir Immune Defic Syndr 2003;32:94-103.
5. Parekh BS, Pau CP, Kennedy MS, Dobbs TL, and McDougal JS: Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res Hum Retroviruses 2001;17:137-146.
6. Li H, Ketema F, Sill AM, Kreisel KM, Cleghorn FR, and Constantine NT: A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection. Int J Infect Dis 2007;11:459-465.
7. Suligoi B, Massi M, Galli C, et al.: Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003;32:424-428.
8. Parekh BS, Kennedy MS, Dobbs T, et al.: Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002;18:295-307.
9. Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, and De Cock KM: The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals [see comments]. Am J Public Health 2001;91:1019-1024.
10. Parekh BS and McDougal JS: Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res 2005;121:510-518.
11. McDougal JS, Pilcher CD, Parekh BS, et al.: Surveillance for HIV-1 incidence using tests for recent infection in resourceconstrained countries. AIDS 2005;19(Suppl 2):S25-30.
12. Wilson KM, Johnson EI, Croom HA, et al.: Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 2004;18:2253-2259.
13. Janssen RS, Satten GA, Stramer SL, et al.: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-48. [Erratum appears in JAMA 1999;281(20): 1893.]
14. Kothe D, Byers RH, Caudill SP, et al.: Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003;33:625-634.
15. Barin F, Meyer L, Lancar R, et al.: Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005;43:4441-4447.
16. Soroka SD, Granade TC, Candal D and Parekh BS: Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol 2005;12:918-921.
17. Hall HI, Song R, Rhodes P, et al.: Estimation of HIV incidence in the United States. JAMA 2008;300:520-529.
18. Hoare A, Wilson DP, Regan DG, Kaldor J and Law MG: Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: Importance of other sexually transmissible infections. Sexual Health 2008;5:169-187.
19. Weinstock H, Dale M, Gwinn M, et al.: HIV seroincidence among patients at clinics for sexually transmitted diseases in nine cities in the United States. J Acquir Immune Defic Syndr 2002;29:478-483.
20. Diaz RS, Kallas EG, Castelo A, Rawal BD, and Busch MP: Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: Estimation of incidence and epidemiological tracing. AIDS 1999;13:1417-1418.
21. McFarland W, Busch MP, Kellogg TA, et al.: Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr 1999;22:484-489.
22. Gupta SB, Gill ON, Graham C, Grant AD, Rogers PA, and Murphy G: What a test for recent infection might reveal about HIV incidence in England and Wales. AIDS 2000;14: 2597-2601.
23. Rutherford GW, Schwarcz SK, and McFarland W: Surveillance for incident HIV infection: New technology and new opportunities. J Acquir Immune Defic Syndr 2000;25(Suppl 2):S115-119.
24. Parekh BS,HuDJ,Vanichseni S, et al.: Evaluation of a sensitive/ less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion, among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses 2001;17:453-458.
25. Young CL, Hu DJ, Byers R, et al.: Evaluation of a sensitive/ less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses 2003;19:481-486.
26. Hall HI, Song R, Rhodes P, et al.: Estimation of HIV incidence in the United States [see comment]. JAMA 2008;300: 520-529.
27. Hu DJ, Vanichseni S, Mock PA, et al.: HIV type 1 incidence estimates by detection of recent infection from a crosssectional sampling of injection drug users in Bangkok:Use of the IgG capture BED enzyme immunoassay. AIDS Res Hum Retroviruses 2003;19:727-730.
28. Nesheim S, Parekh B, Sullivan K, et al.: Temporal trends in HIV Type 1 incidence among inner-city childbearing women in Atlanta: Use of the IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 2005;21:537-544.
29. Saphonn V, Parekh BS, Dobbs T, et al.: Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia, 1999-2002. J Acquir Immune Defic Syndr 2005; 39:587-592.
30. Priddy FH, Pilcher CD, Moore RH, et al.: Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007;44:196-202.
31. Rehle T, Shisana O, Pillay V, Zuma K, Puren A, and Parker W: National HIV incidence measures-new insights into the South African epidemic [see comment]. South African Med J Suid-Afrikaanse Tydskrif Vir Geneeskunde 2007;97:194-199.
32. Scheer S, Chin, C-S, Buckman, A, and McFarland, W: Estimation of HIV incidence in San Francisco. AIDS 2009;23: 533-534.
33. McDougal JS, Parekh BS, Peterson ML, et al.: Comparison of HIV type 1 incidence observed during longitudinal followup with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006;22:945-952.
34. Hargrove JW, Humphrey JH, Mutasa K, et al.: Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 2008;22:511-518.
35. Chawla A, Murphy G, Donnelly C, et al.: Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)- seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007;45:415-420.
36. Sakarovitch C, Rouet F, Murphy G, et al.: Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007;45: 115-122.
37. http://www.hiv.lanl.gov/content/hiv-db/EPILIGN/EPI .html.
38. Hu DJ, Vanichseni S, Mastro TD, et al.: Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001;15: 683-691.
39. Parekh B, Schwimmbeck PW, Buchmeier MJ.: High efficiency purification of anti-peptide antibodies on thiopropyl sepharose immunoadsorbants. Peptide Res 1989;2: 249-252.
40. Marcolino PT, Silva DA, Leser PG, Camargo ME and Mineo JR: Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting. Clin Diagnost Lab Immunol 2000;7: 384-389.
41. Rossi CL: A simple, rapid enzyme-linked immunosorbent assay for evaluating immunoglobin G antibody avidity in toxoplasmosis. Diagnost Microbiol Infect Dis 1998;30:25-30.
42. Gray JJ: Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation. J Virol Methods 1995;52:95-104.
43. Wreghitt TG, Gray JJ, Aloyisus S, Contreras M, and Barbara JA: Antibody avidity test for recent infection with hepatitis C virus. Lancet 1990;335:789.
44. Suligoi B, Galli C, Massi M, et al.: Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol 2002;40:4015-4020.
45. Dobbs T, Kennedy S, Pau CP, McDougal JS, and Parekh BS: Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004;42:2623-2628.
46. Hayashida T, Gatanaga H, Tanuma J, and Oka S: Effects of low HIV type 1 load and antiretroviral treatment on IgGcapture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 2008;24:495-498.